Subcutaneous and Substernal Implantable Cardioverter Defibrillator, Surgical 106

Table of Content

Description & Definitions
Criteria
Document History
Coding
Special Notes
References
Keywords

Effective Date	10/1/2025
Next Review Date	7/2026
Coverage Policy	Surgical 106
Version	7

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Description & Definitions:

Subcutaneous Implantable Cardioverter Defibrillator is a device that is implanted under the skin (subcutaneous). It provides an electric shock to the heart (defibrillation) for the treatment of an abnormally rapid heartbeat that originates from the lower chambers of the heart.

Substernal Implantable Cardioverter-Defibrillator System is an electronic device with a generator which is implanted under the left side rib cage with lead wires that reside under the sternum instead of through the veins, and closer to the heart. The device monitors abnormal heart rhythms; when detected a shock is sent to the heart to restore a normal rhythm, it also has the ability to deliver anti-tachycardia pacing (ATP) and bradycardia pacing or resynchronization therapy.

Criteria:

Subcutaneous Implantable Cardioverter Defibrillator is medically necessary for **ALL** of the following:

- Individual with accepted clinical indications for an automatic implantable cardioverter defibrillator
- Individual for whom pacing for bradycardia or ventricular tachycardia (VT) termination is neither needed nor anticipated and **1 or more** of the following:
  - Individual has congenital heart disease with right to left shunting
  - Individual has limited access to the right ventricle
  - Individual has inadequate vascular access to allow for placement of an implantable device
  - Individual has no conventional pocket sight due to previous device related infections or other chronic indwelling catheters preventing access to a potential pocket site.

Subcutaneous Implantable Cardioverter Defibrillator is considered **not medically necessary** for any use other than those indicated in clinical criteria.

Substernal Implantable Cardioverter-Defibrillator System is considered **not medically necessary** for any indication.

Document History:

Revised Dates:

- 2025: July – Implementation date of October 1, 2025. Annual review completed. Added non-coverage information for substernal ICDs including coding. No criteria changes for subcutaneous ICDs. References and coding updated as needed.
- 2022: July
- 2021: July
- 2019: December
- 2016: January, April
- 2015: July

Reviewed Dates:

- 2024: July – Annual review completed. No changes needed. References and coding updated as needed.
- 2023: July
- 2021: November
- 2020: November
- 2018: August
- 2017: December
- 2016: March
- 2015: March

Origination Date: April 2014

Coding:

Medically necessary with criteria:

Coding	Description
33270	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed
33271	Insertion of subcutaneous implantable defibrillator electrode
33272	Removal of subcutaneous implantable defibrillator electrode
33273	Repositioning of previously implanted subcutaneous implantable defibrillator electrode

Considered Not Medically Necessary:

Coding	Description
0571T	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed
0572T	Insertion of substernal implantable defibrillator electrode
0573T	Removal of substernal implantable defibrillator electrode
0574T	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter

0577T	Electrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results
0580T	Removal of substernal implantable defibrillator pulse generator only
0614T	Removal and replacement of substernal implantable defibrillator pulse generator

The preceding codes are included above for informational purposes only and may not be all inclusive. Additionally, inclusion or exclusion of a treatment, procedure, or device code(s) does not constitute or imply member coverage or provider reimbursement.

Special Notes: *

- Coverage: See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.
    - Refer to Wearable External Cardioverter Defibrillators - DME 24 for LifeVest coverage
- Application to Products: Policy is applicable to Sentara Health Plan Virginia Medicaid products.
- Authorization Requirements: Pre-certification by the Plan is required.
    - Note: Single chamber or dual chamber cardiac pacemakers and non-subcutaneous implantable cardiac defibrillators are covered without medical review.
- Special Notes:
    - This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.
    - Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.
    - The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.
    - Service authorization requests must be accompanied by sufficient clinical records to support the request. Clinical records must be signed and dated by the requesting provider withing 60 days of the date of service requested.

References:

References used include but are not limited to the following: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

§ 870.3610 Implantable pacemaker pulse generator. (2008, Jun 23). Retrieved Jun 23, 2025, from Code of Federal Regulations: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-870/subpart-D/section-870.3610

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Hea. (2018, Aug 01). Retrieved Jun 23, 2025, from American Heart Association: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549

(2024, Mar 14). Retrieved Jun 18, 2025, from MCG 28th Edition: https://careweb.careguidelines.com/ed28/index.html

EVOLENT CLINICAL GUIDELINE 321 FOR IMPLANTABLE CARDIOVERTER DEFIBRILLATOR. (2025, Jan 01). Retrieved Jun 19, 2025, from Evolent (formerly NIA) RadMD: https://www.radmd.com/RadMD/assets/Clinical%20Guidelines//Evolent%20Standard%20Guideline%202025/Evolent%20Clinical%20Guideline%20321%20for%20Implantable%20Cardioverter%20Defibrillator%202025.pdf

Hospital Manual - Chapter IV: Covered Services and Limitations. (2024, Aug 28). Retrieved Jun 23, 2025, from Virginia Department of Medical Assistance Services: https://vamedicaid.dmas.virginia.gov/sites/default/files/2024-08/Hospital%20Chapter%20IV%20%28updated%208.28.24%29_Final.pdf

Implantable Cardioverter Defibrillators 2024-11-17. (2024, Nov 17). Retrieved Jun 19, 2025, from Carelon Medical Benefits Management: https://guidelines.carelonmedicalbenefitsmanagement.com/implantable-cardioverter-defibrillators-2024-11-17/

Knight, B. (2024, Apr 15). Implantable cardioverter-defibrillators: Choosing a device and system descriptions. Retrieved Jun 19, 2025, from UpToDate: https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-choosing-a-device-and-system-descriptions?search=substernal%20ICD&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H963847758

LCA: Billing and Coding: Implantable Automatic Defibrillators (A56343). (2025, Apr 01). Retrieved Jun 20, 2025, from Centers for Medicare and Medicaid Services: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56343&ver=13&keyword=cardioverter&keywordType=starts&areaId=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1

NCD: Implantable Cardioverter Defibrillators (ICDs) (20.4). (2023, Jul 31). Retrieved Jun 20, 2025, from Centers for Medicare and Medicaid Services: https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=110&ncdver=5&keyword=cardioverter&keywordType=starts&areaId=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1

product code LWS. (2025, Jun 23). Retrieved Jun 23, 2025, from U.S. Food and Drug Administration: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start_search=1&applicant=&tradename=&productcode=LWS&pmanumber=p&advisorycommittee=&docketnumber=&supplementtype=&expeditedreview=&ivdproducts=off&decisiondatefrom=1/1/2025&decisiondateto=1/

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for Prevention of Sudden Cardiac Death. (2023, May 31). Retrieved Jun 23, 2025, from Hayes - a symplr company: https://evidence.hayesinc.com/report/dir.sicd2909

Keywords:

Subcutaneous Implantable Cardioverter Defibrillator, ICD, SHP Surgical 106, congenital heart disease, right to left shunting, Substernal implantable cardioverter-defibrillator system